[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346538-105":59,"doc-detail-346538-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-and-clinicopathological-biomarkers-predicting-brain-metastasis-in-triple-negative-breast-cancer-a-systematic-review","Molecular and Clinicopathological Biomarkers Predicting Brain Metastasis in Triple-Negative Breast Cancer - A Systematic Review","","Almost half of patients with triple-negative breast cancer develop brain metastasis, reflecting poor prognosis and making biomarker-driven prediction essential. This systematic review extracts peer-reviewed clinicopathological biomarkers of TNBC brain metastasis from publications spanning 2010–2025 across major databases. A total of 130 studies (60 clinical, 70 pre-clinical) are included, highlighting transcriptomic analyses, growth factor receptors, and immune microenvironment markers, with additional focus on circulating biomarkers for early detection. Further biomarker characterization supports risk stratification, trial design, patient selection, and therapeutic development.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-and-clinicopathological-biomarkers-predicting-brain-metastasis-in-triple-negative-breast-cancer-a-systematic-review/346538/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-and-clinicopathological-biomarkers-predicting-brain-metastasis-in-triple-negative-breast-cancer-a-systematic-review/346538.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem does the review focus on?","Question",{"text":112,"@type":113},"The review addresses triple-negative breast cancer patients who develop brain metastasis, a marker of poor prognosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were studies selected for the systematic review?",{"text":117,"@type":113},"Peer-reviewed publications from 2010 to 2025 were extracted from PubMed, Scopus, Embase, Cochrane, and Web of Science, including studies evaluating clinicopathological biomarkers of TNBC brain metastasis.",{"name":119,"@type":110,"acceptedAnswer":120},"What biomarker types were most frequently identified?",{"text":121,"@type":113},"Transcriptomic studies, growth factor receptors, and immune microenvironment markers were most common, reported as 37, 19, and 17 studies respectively.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346538,1791499872,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review  \nMolecular and Clinicopathological Biomarkers Predicting Brain Metastasis in Triple-Negative Breast Cancer: A Systematic Review  \nSavi Agarwal 1,†, Pasha Mehranpour 2,†, Anjani Chawla 3, Carissa Vaish 4, Simon Han 1, Isaac Yang 1 and Madhuri Wadehra 5, *  \nAcademic Editor: Anna Makuch-Kocka  \nReceived: 30 December 2025  \nRevised: 3 February 2026  \nAccepted: 13 February 2026  \nPublished: 16 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Neurosurgery, University of California, Los Angeles, CA 90095, USA; [saviagarwal@mednet.ucla.edu](saviagarwal@mednet.ucla.edu) (S.A.); [simonhan@mednet.ucla.edu](simonhan@mednet.ucla.edu) (S.H.); [iyang@mednet.ucla.edu](iyang@mednet.ucla.edu) (I.Y.)  \n2 School of Medicine, California University of Science and Medicine, 1501 Violet Street, Colton, CA 92324, USA; [pasha.mehranpour@md.cusm.edu](pasha.mehranpour@md.cusm.edu)  \n3 Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada; [chawla23@mcmaster.ca](chawla23@mcmaster.ca)  \n4 School of Public Health, University of Washington, Seattle, WA 98195, USA; [cvaish@uw.edu](cvaish@uw.edu)  \n5 Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095, USA  \n* [Correspondence: mwadehra@mednet.ucla.edu](Correspondence: mwadehra@mednet.ucla.edu)[ ](Correspondence: mwadehra@mednet.ucla.edu)† These authors contributed equally to this work.  \nAbstract  \nAlmost half of patients with triple-negative breast cancer (TNBC) develop brain metastasis (TNBCBM), a marker of poor prognosis. TNBC is a more aggressive breast cancer subtype which lacks ER, PR, and HER2 expression, and thus, exploring predictive biomarkers is crucial to improving TNBCBM outcomes through targeted therapy. To curate these biomarkers, peer-reviewed publications from 2010 to 2025 were extracted from PubMed, Scopus, Embase, Cochrane, and Web of Science if they evaluated clinicopathological biomarkers of TNBCBM. A total of 130 studies (60 clinical and 70 pre-clinical) were included. Publications most often featured transcriptomic studies, growth factor receptors, and immune microenvironment markers with 37, 19, and 17 studies identified, respectively. While TNBC aggressiveness has been linked to metastasis, advancing stage, and poor prognosis, several studies focused on utilizing circulating protein and transcriptomic biomarkers for early detection. While few pathways appeared specifically for TNBCBM, investigating these biomarkers further may allow for improved risk stratification, clinical trial design, patientselection, and therapeutic development. Identification of the most promising biomarkers will pave the way for improved prognosis of the most lethal complications of TNBC.  \nKeywords: triple-negative breast cancer; brain metastasis; predictive biomarkers; metastatic mechanisms; prognostic indicators  \n1. Introduction  \nMetastatic lesions account for about 15% of all central nervous system (CNS) tumors, with lung cancer being the most common source (35%), followed by breast cancer (30%) . Of the breast cancer subtypes, triple-negative breast cancer (TNBC) is the most common subtype to metastasize to the CNS [1] . TNBC is a particularly aggressive form of breast cancer, defined by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [2,3] . The lack of these molecular features posed clinical challenges in treatment, as established therapies that target receptors, such as hormonal interventions or trastuzumab, were rendered ineffective. Patients with TNBC therefore experience higher rates of recurrence, metastasis, and mortality  \ncompared to other forms of breast cancer, with half of all primary TNBC patients remaining susceptible to br","cbCaingGmjjCkh2L","https://ap.wps.com/l/cbCaingGmjjCkh2L","pdf",1367825,26,"English","# Abstract\n# 1. Introduction\n# 2. Materials and Methods","[{\"question\":\"What clinical problem does the review focus on?\",\"answer\":\"The review addresses triple-negative breast cancer patients who develop brain metastasis, a marker of poor prognosis.\"},{\"question\":\"How were studies selected for the systematic review?\",\"answer\":\"Peer-reviewed publications from 2010 to 2025 were extracted from PubMed, Scopus, Embase, Cochrane, and Web of Science, including studies evaluating clinicopathological biomarkers of TNBC brain metastasis.\"},{\"question\":\"What biomarker types were most frequently identified?\",\"answer\":\"Transcriptomic studies, growth factor receptors, and immune microenvironment markers were most common, reported as 37, 19, and 17 studies respectively.\"}]","Molecular and Clinicopathological Biomarkers Predicting Brain Metastasis in Triple-Negative Breast Cancer - A Systematic Review | PDF",1790061888,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38b6a82c91b057fe54a0ed1bd5826b43.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b090ab4efb40468ca35207a708fce557.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b0a0bdb638ea7bc2594b9d09d7ffefb.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60ef3e87a4413955f5d066d000b809f4.webp",980,1385]